非肝硬化性门静脉高压症的研究现状

李晓珂; 薛舒文; 杨新乐; 王彤; 季慧范

doi:10.3969/j.issn.1001-5256.2020.11.038

非肝硬化性门静脉高压症的研究现状

DOI: 10.3969/j.issn.1001-5256.2020.11.038

吉林大学第一医院肝病科

详细信息

中图分类号: R575
计量
- 文章访问数: 717
- HTML全文浏览量: 24
- PDF下载量: 161
- 被引次数: 0
出版历程
- 收稿日期: 2020-02-20
- 出版日期: 2020-11-20

Research advances in non-cirrhotic portal hypertension

Department of Hepatology,The First Hospital of Jilin University

摘要

摘要:
门静脉高压症是指由于各种原因导致门静脉系统压力升高所引起的一组临床综合征,最常见的病因是肝硬化,但仍有10%～20%的门静脉高压症继发于各种非肝硬化疾病,统称这类疾病为非肝硬化性门静脉高压症（NCPH）。NCPH是一组高度异质性疾病,总结了几种不同类型NCPH疾病的临床特征、病理特征及诊治要点,以期提高临床医生对此类疾病的认识。
- 高血压,门静脉 /
- 病理过程 /
- 病理学,临床 /
- 诊断显像
Abstract:
Portal hypertension is a group of clinical syndromes caused by increased pressure of the portal vein system due to various reasons,with liver cirrhosis as the most common cause,but 10%-20% of portal hypertension cases are secondary to various non-cirrhotic diseases,which are collectively referred to as non-cirrhotic portal hypertension( NCPH). NCPH is a group of highly heterogeneous diseases. This article summarizes the clinical features,pathological features,and key diagnosis and treatment points of different types of NCPH,in order to improve the understanding of these diseases among clinicians.
- hypertension,portal /
- pathologic processes /
- pathology,clinical /
- diagnostic imaging

HTML全文

参考文献(40)

[1] RAJESH S,MUKUND A,SUREKA B,et al. Non-cirrhotic portal hypertension:An imaging review[J]. Abdom Radiol(NY),2018,43(8):1991-2010.

[2] CUNNINGHAM ME,PARASTANDEH-CHEHR G,CEROCCHI O,et al. Noninvasive predictors of high-risk varices in patients with non-cirrhotic portal hypertension[J]. Can J Gastroenterol Hepatol,2019,2019:1808797.

[3] ZHANG BJ,HAN GH,FAN DM. Research advances in noncirrhotic portal hypertension[J]. J Clin Hepatol,2016,32(2):245-249.(in Chinese)张博静，韩国宏，樊代明．非肝硬化性门静脉高压症的研究现状[J]．临床肝胆病杂志，2016,32(2):245-249.

[4] PARGEWAR SS,DESAI SN,RAJESH S,et al. Imaging and radiological interventions in extra-hepatic portal vein obstruction[J]. World J Radiol,2016,8(6):556-570.

[5] KHANNA R,SARIN SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction[J]. Hepatol Int,2018,12(Suppl 1):148-167.

[6] SARIN SK,SOLLANO JD,CHAWLA YK,et al. Consensus on extra-hepatic portal vein obstruction[J]. Liver Int,2006,26(5):512-519.

[7] JABEEN S,ROBBANI I,CHOH NA,et al. Spectrum of biliary abnormalities in portal cavernoma cholangiopathy(PCC)secondary to idiopathic extrahepatic portal vein obstruction(EHPVO)-a prospective magnetic resonance cholangiopancreaticography(MRCP)based study[J]. Br J Radiol,2016,89(1068):20160636.

[8] de FRANCHIS R,Baveno VI Faculty. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752.

[9] TEFFERI A. Primary myelofibrosis:2019 update on diagnosis,risk-stratification and management[J]. Am J Hematol,2018,93(12):1551-1560.

[10] ALVAREZ-LARRAN A,ABRALDES JG,CERVANTES F,et al. Portal hypertension secondary to myelofibrosis:A study of three cases[J]. Am J Gastroenterol,2005,100(10):2355-2358.

[11] ABU-HILAL M,TAWAKER J. Portal hypertension secondary to myelofibrosis with myeloid metaplasia:A study of 13 cases[J]. World J Gastroenterol,2009,15(25):3128-3133.

[12] SONG ZQ,ZHOU LY. A clinical analysis of six cases of portal hypertension secondary to primary myelofibrosis and review of literatures[J]. Chin J Intern Med,2010,49(10):845-847.(in Chinese)宋志强，周丽雅．原发性骨髓纤维化继发门脉高压症六例分析并文献复习[J]．中华内科杂志，2010,49(10):845-847.

[13] RIGGIO O,GIOIA S,PENTASSUGLIO I,et al. Idiopathic noncirrhotic portal hypertension:Current perspectives[J]. Hepat Med,2016,8:81-88.

[14] FIEL MI,SCHIANO TD. Idiopathic noncirrhotic portal hypertension[J]. Semin Diagn Pathol,2019,36(6):395-403.

[15] SCHOUTEN JN,GARCIA-PAGAN JC,VALLA DC,et al. Idiopathic noncirrhotic portal hypertension[J]. Hepatology,2011,54(3):1071-1081.

[16] BAO WC,QI XS,TANG SH,et al. An excerpt of the Japanese research group on IPH:Diagnosis and treatment guidelines for aberrant portal hemodynamics(2017)[J]. J Clin Hepatol,2017,33(3):432-434.(in Chinese)暴文春，祁兴顺，汤善宏，等．《2017年日本特发性门静脉高压研究组:门静脉血流动力学异常相关疾病诊治指南》摘译[J]．临床肝胆病杂志，2017,33(3):432-434.

[17] LI Y,ZHOU XG,YANG K,et al. Analysis of pathological features of 42 cases with idiopathic non-cirrhotic portal hypertension[J]. Chin J Dr,2020,48(3):291-294.(in Chinese)李越，周新刚，杨坤，等．42例特发性非肝硬化性门脉高压的病理特点分析[J]．中国临床医生杂志，2020,48(3):291-294.

[18] KHANNA R,SARIN SK. Non-cirrhotic portal hypertensiondiagnosis and management[J]. J Hepatol,2014,60(2):421-441.

[19] XU HF,DING HG. Diagnosis and treatment of pre-hepatic(sinusoidal)non-cirrhotic portal hypertension and related difficulties[J]. J Clin Hepatol,2019,35(1):13-17.(in Chinese)徐航飞，丁惠国．肝(窦)前型非肝硬化门静脉高压症的诊断与治疗及其面临的困境[J]．临床肝胆病杂志，2019,35(1):13-17.

[20] de GOTTARDI A,RAUTOU PE,SCHOUTEN J,et al. Porto-sinusoidal vascular disease:Proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol,2019,4(5):399-411.

[21] ZHU B,DU Z,WANG Z,et al. Congenital hepatic fibrosis in children and adults:Clinical manifestations, management,and outcome-case series and literature review[J]. Gastroenterol Res Pract,2020,2020:8284274.

[22] LOCATELLI L,CADAMURO M,SPIRLìC,et al. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis[J]. Hepatology,2016,63(3):965-982.

[23] PARKASH A,CHEEMA HA,MALIK HS,et al. Congenital hepatic fibrosis:Clinical presentation,laboratory features and management at a tertiary care hospital of Lahore[J]. J Pak Med Assoc,2016,66(8):984-988.

[24] KRITHARIS A,AL-SAMKARI H,KUTER DJ. Hereditary hemorrhagic telangiectasia:Diagnosis and management from the hematologist’s perspective[J]. Haematologica,2018,103(9):1433-1443.

[25] ELISABETTA B,SILVIA G,SAVERIO A,et al. Liver involvement in hereditary hemorrhagic telangiectasia[J]. Abdom Radiol,2018,43(8):1920-1930.

[26] RUAN ZB,JIAO J,MIN DY,et al. Clinical and imaging features of hepatic hereditary hemorrhagic telangiectasia[J]. J Clin Radiol,2018,37(8):1314-1319.(in Chinese)阮志兵，焦俊，闵定玉，等．肝脏遗传性出血性毛细血管扩张症的CT表现特点及漏诊、误诊分析[J]．临床放射学杂志，2018,37(8):1314-1319.

[27] ZHAO JQ,HUO F,WANG SP,et al. Liver transplantation treats hepatic hereditary hemorrhagic telangiectasia:A case report[J].Chin J Organ Transplant,2017,38(3):184-187.(in Chinese)赵纪强，霍枫，汪邵平，等．肝移植治疗肝脏遗传性毛细血管扩张症一例[J]．中华器官移植杂志2017,38(3):184-187.

[28] Cooperative Group for Hepatic and Gal Diseases,Chinese Society of Gastroenterology,Chinese Medical Association. Expert consensus on diagnosis and treatment of quinazoline alkaloidsrelated sinusoidal obstruction syndrome(2017,Nanjing)[J]. J Clin Hepatol,2017,33(9):1627-1637.(in Chinese)中华医学会消化病学分会肝胆疾病协作组．吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年，南京)[J]．临床肝胆病杂志，2017,33(9):1627-1637.

[29] YANG XQ,YE J,LI X,et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome:Pathogenesis,clinical manifestations,diagnosis,treatment,and outcomes[J].World J Gastroenterol,2019,25(28):3753-3763.

[30] NASSEREDDINE S,ALSUBAIT S,TABBARA I. Sinusoidal obstruction syndrome(veno-occlusive disease)following hematopoietic stem cell transplant:Insights and therapeutic advances[J]. Anticancer Res,2018,38(5):2597-2605.

[31] European Association for the Study of the Liver. EASL clinical practice guidelines:Vascular diseases of the liver[J]. J Hepatol,2016,64(1):179-202.

[32] LIU ZL,FAN ZP,GOU YS,et al. Clinical features,pathogenesis,and diagnosis and treatment of different types of hepatic sinusoidal obstruction syndrome[J]. J Clin Hepatol,2019,35(1):208-212.(in Chinese)刘贞利，范作鹏，勾钰淞，等．不同类型肝窦阻塞综合征的临床特征、发病机制与诊治[J]．临床肝胆病杂志，2019,35(1):208-212.

[33] DAS CJ,SONEJA M,TAYAL S,et al. Role of radiological imaging and interventions in management of Budd-Chiari syndrome[J]. Clin Radiol,2018,73(7):610-624.

[34] DANG XW,LI LH,LI L,et al. Application value of clinical typing in the treatment of Budd-Chiari syndrome[J]. Chin J Dig Surg,2016,15(7):696-701.(in Chinese)党晓卫，李路豪，李林，等．布加综合征临床分型在其治疗中的应用价值[J]．中华消化外科杂志，2016,15(7):696-701.

[35] KHAN F,ARMSTRONG MJ,MEHRZAD H,et al. Review article:A multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome[J]. Aliment Pharmacol Ther,2019,49(7):840-863.

[36] LIU L,QI XS,ZHAO Y,et al. Budd-Chiari syndrome:Current perspectives and controversies[J]. Eur Rev Med Pharmacol Sci,2016,20(15):3273-3281.

[37] GOEL RM,JOHNSTON EL,PATEL KV,et al. Budd-Chiari syndrome:Investigation,treatment and outcomes[J]. Postgrad Med J,2015,91(1082):692-697.

[38] VALLA DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J]. Hepatol Int,2018,12(Suppl 1):168-180.

[39] GRUS T,LAMBERT L,GRUSOVG,et al. Budd-Chiari syndrome[J]. Prague Med Rep,2017,118(2-3):69-80.

[40] HU Q,XIANG CH. Current status regarding diagnosis and management of idiopathic portal hypertension[J]. Chin J Gen Surg,2016,8(1):117-124.(in Chinese)朱青，项灿宏．特发性门静脉高压症的诊治现状[J]．中国普通外科杂志，2019,28(1):117-124.

施引文献

资源附件(0)

访问统计